[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-nerve-tissue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-nerve-tissue":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,100,139,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":60,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100355699","phase-1-hsv-g207-in-children-with-recurrent-or-refractory-cerebellar-brain-tumors-100355699",false,"NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* Lesion must be ≥ 1.0 cm ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking\n* Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea)\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to entering this study (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥ 7 days). For viral therapy, patients must have received viral therapy ≥ 3 months prior to study entry and have recovered from all acute toxicities potentially related to the agent.\n* Monoclonal antibodies: The patient must have received last dose ≥ 21 days prior.\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to study entry.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to study entry.\n* Normal hematological, renal and liver function (absolute neutrophil count \\> 1000\u002Fmm3, platelets \\> 100,000\u002Fmm3, prothrombin time (PT) or partial thromboplastin time (PTT) \\\u003C 1.3 x control, creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, total bilirubin \\\u003C 1.5 mg\u002Fdl, transaminases \\\u003C 3 times above the upper limits of the institutional norm)\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Patient life expectancy must be at least 8 weeks\n* Written informed consent in accordance with institutional and FDA guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Any treatment outside the allowable guidelines outlined in section 5.1.\n* Diffuse, widespread, abnormal tumor pattern involving 3 or more lobes of the brain\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or CNS infection \\\u003C 3 months prior, or receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Required steroid increase within 1 week prior to G207 inoculation or patients requiring \\>2 mg of dexamethasone daily\n* Known HIV seropositivity\n* Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone).\n* Other current malignancy\n* Concurrent anticancer or investigational drug","ALL","3 Years","21 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[61,62,28,63,64,65,66,67,68,69,70,71,72,73,74,75,30,76,77,78,79,80,81,82,83,56,55,84,85,86],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","RECRUITING","2026-05-13",{"date":90,"type":91},"2026-05-15","ACTUAL",{"date":93,"type":91},"2019-09-12",{"date":95,"type":21},"2027-09-01",{"name":97,"class":98},"M.D. Anderson Cancer Center","OTHER",3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100554275","phase-3-a-prospective-pivotal-study-to-evaluate-the-efficacy-and-safety-of-avastin-bevacizumab-bev-with-or-without-microbubble-mediated-focused-ultrasound-fus-mb-using-navifus-system-in-recurrent-glioblastoma-multiforme-patients-100554275","NCT06496971","A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","A Prospective, Randomized, Standard of Care Controlled, Parallel, Open-Label, Multicenter Pivotal Study to Evaluate the Efficacy and Safety of Avastin® in Combination With NaviFUS System Compared With Avastin® Alone for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)","Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years of age at the time of study enrollment.\n2. Body mass index (BMI) ≥ 17 kg\u002Fm2.\n3. Patients diagnosed with glioblastoma must have unequivocal evidence of recurrence, as determined by contrast-enhanced magnetic resonance imaging (CE-MRI), following prior radiotherapy and temozolomide chemotherapy.\n4. Patients may have undergone surgery for recurrence. The patients should have completed surgery and adequately recovered prior to the time of study enrollment.\n5. Patients must have radiographic evidence of either at least an 80% resection of enhancing tumor following recurrence or a maximal measurable residual tumor ≤ 20 cm3.\n6. If patients are receiving corticosteroids, they must have been on a stable or decreasing dose of corticosteroids for at least 1 week prior to the planned first treatment.\n7. At the time of study enrollment, the minimum interval since the last event:\n\n   * 4 weeks out from invasive procedures (e.g., open biopsy, surgical resection, significant traumatic injury, or any other major surgery involving entry into a body cavity) and the patient must have recovered from the effects of surgery\n   * 1 week out from minor surgical procedures or core biopsies\n8. Patients must have recovered from the toxic effects of prior therapy at the time of study enrollment as follows:\n\n   * 4 weeks out from any investigational drug or device\n   * 4 weeks out from chemotherapy\n   * 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen (e.g., Carmustine (BCNU))\n   * 12 weeks out from completion of radiotherapy\n9. Patients should have a life expectancy ≥ 12 weeks.\n10. Patients must have Karnofsky Performance Status (KPS) ≥ 70.\n11. Adequate hematopoietic, renal, hepatic, and coagulation function, defined as:\n\n    * Hemoglobin ≥ 10 g\u002FdL\n    * Platelets ≥ 100,000\u002Fmm3\n    * Neutrophils ≥ 1,500\u002Fmm3\n    * Serum creatinine ≤ 1.5 × upper limit of normal (ULN)\n    * Urine protein creatinine ratio (UPCR) \\\u003C 1 or urine dipstick for proteinuria ≤ 2+\n    * Alanine aminotransferase (ALT) \\\u003C 3 × ULN\n    * Aspartate aminotransferase (AST) \\\u003C 3 × ULN\n    * Total bilirubin (TBL) \\\u003C 2 × ULN\n    * Prothrombin time ≤ 1.5 x ULN\n    * International Normalized Ratio (INR) \\\u003C 1.5 These tests must be conducted within 2 weeks prior to the planned first treatment.\n12. The central of FUS exposure region is located with a minimum distance of at least 30 mm beneath the skull bone.\n13. Females of childbearing potential must have a negative pregnancy test documented within 2 weeks prior to first treatment. Females of childbearing potential and male patients with partners of childbearing potential must agree to adhere to an acceptable method of contraception (as outlined below) from prior to the first study treatment until at least 6 months after the completion of last treatment. Standard acceptable methods of contraception include the use of highly effective methods such as hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, spermicide, vasectomy, intrauterine device, or abstinence from sexual activity.\n14. Patients are able and willing to have peripheral intravenous (IV) line placement of Bevacizumab and are able to have hair shaved (either whole head or in the region where the coupling membrane will touch) prior to FUS treatment if assigned to treatment group.\n15. Patients or their legal representatives are able to provide written informed consent for participation in the trial and patients are willing to comply the procedures (i.e., study-related assessments), instructions, and restrictions outlined in this study in the duration of the study. Informed consent should also be given for biological materials and diagnostic imaging to be stored and used for future research on brain tumors.\n\nExclusion Criteria:\n\n1. Patients who have radiographic evidence of multifocal enhancing tumors.\n2. Patients who have undergone previous treatment with anti-angiogenic therapy, including Bevacizumab, or other VEGF inhibitors or VEGF-receptor signaling inhibitors.\n3. Patients who have previously received Carmustine wafers implantation during re-operation.\n4. Patients who have previously received or are currently undergoing tumor treating fields (TTF) treatment.\n5. Uncontrolled or significant cardiovascular disease, including any of the following:\n\n   * New York Heart Association (NYHA) Grade II or above congestive heart failure (CHF) within 12 months prior to study enrollment\n   * Unstable angina pectoris\n   * Medical history of myocardial infarction within 6 months prior to study enrollment\n   * Cardiac shunt\n6. Stroke (except for transient ischemic attack; TIA) within 6 months prior to study enrollment.\n7. Patients with implanted electronic device, for example, implanted cardioverter-defibrillator (ICD), cardiac pacemaker, permanent medication pumps, cochlear implants, responsive neurostimulator (RNS), deep brain stimulation (DBS), or other electronic devices implanted in the brain. Patients with contraindications for MRI as judged by Investigator, including non-MRI compatible metallic implant(s).\n8. Patients with inadequately controlled hypertension, defined as systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg while on medication, within 2 weeks prior to first treatment.\n9. Patients with evidence of any thrombotic or hemorrhagic events, including but not limited to:\n\n   * Inherited bleeding diathesis or significant coagulopathy with the risk of bleeding (i.e., in the absence of therapeutic anticoagulation).\n   * History of pulmonary haemorrhage\u002Fhaemoptysis ≥ grade 2 according to the CTCAE version 5.0 criteria within 1 month prior to study enrollment\n   * Arterial or venous thrombosis (e.g., pulmonary embolism) within 3 months prior to study enrollment\n10. Patients with unstable pulmonary disease or chronic obstructive pulmonary disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study enrollment.\n11. Patients who have psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n12. Known HIV-positive patient, however, that HIV testing is not required for entry into this study.\n13. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study enrollment.\n14. History or evidence of active gastroduodenal ulcer, gastrointestinal perforations\u002Ffistula, or intra-abdominal abscess within 6 months prior to study enrollment.\n15. Receiving anticoagulant (e.g., warfarin or LMW heparin) or antiplatelet (e.g., aspirin) therapy within 1 week prior to beginning treatment.\n16. Known sensitivity\u002Fallergy to Magnetic Resonance Imaging (MRI) contrast agents, Computer Tomography (CT) contrast agents, SonoVue®, Bevacizumab, or any of their components.\n17. Pregnant (positive pregnancy test) or breast-feeding women.\n18. Use of any recreational drugs or history of drug addiction.\n19. Other severe concurrent and\u002For uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection, uncontrolled epilepsy, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol.\n20. Any other condition that, in the Investigator's discretion, might increase the risk to the patients or compromise the evaluation of the clinical trial endpoints.","18 Years","80 Years",{"count":110,"type":21},32,[112],"PHASE3","This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.",[28,115,116,62,117,61,30,46],"Glioblastoma","Glioblastoma Multiforme, Adult","Brain Tumor",[119,120,121,122,123,124,125,126,127],"NaviFUS System","Blood-Brain Barrier Opening","Focused Ultrasound","FUS","Low-Intensity Focused Ultrasound","LIFU","Bevacizumab","BEV","Avastin","2026-04-06",{"date":130,"type":91},"2026-04-09",{"date":132,"type":91},"2024-11-08",{"date":134,"type":21},"2027-03-31",{"name":136,"class":137},"NaviFUS Corporation","INDUSTRY",2,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},"100541415","phase-1-safety-and-efficacy-of-bevacizumab-in-combination-with-navifus-system-for-the-treatment-of-recurrent-glioblastoma-multiforme-rgbm-100541415","NCT06329570","Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)","A Prospective, Open-Label, Single-Arm Pilot Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)","Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years of age at the time of study enrollment.\n2. Body mass index (BMI) ≥ 17 kg\u002Fm2.\n3. Patients diagnosed with glioblastoma must have unequivocal evidence of recurrence, as determined by contrast-enhanced magnetic resonance imaging (CE-MRI), following prior radiotherapy and temozolomide chemotherapy.\n4. Patients may have undergone surgery for recurrence. The patients should have completed surgery and adequately recovered prior to the time of study enrollment.\n5. Patients must have radiographic evidence of either at least an 80% resection of enhancing tumor following recurrence or a maximal measurable residual tumor ≤ 20 cm3.\n6. If patients are receiving corticosteroids, they must have been on a stable or decreasing dose of corticosteroids for at least 1 week prior to the planned first treatment.\n7. At the time of study enrollment, the minimum interval since the last event:\n\n   * 4 weeks out from invasive procedures (e.g., open biopsy, surgical resection, significant traumatic injury, or any other major surgery involving entry into a body cavity) and the patient must have recovered from the effects of surgery\n   * 1 week out from minor surgical procedures or core biopsies\n8. Patients must have recovered from the toxic effects of prior therapy at the time of study enrollment as follows:\n\n   * 4 weeks out from any investigational drug or device\n   * 4 weeks out from chemotherapy\n   * 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen (e.g., Carmustine (BCNU))\n   * 12 weeks out from completion of radiotherapy\n9. Patients should have a life expectancy ≥ 12 weeks.\n10. Patients must have Karnofsky Performance Status (KPS) ≥ 70.\n11. Adequate hematopoietic, renal, hepatic, and coagulation function, defined as:\n\n    * Hemoglobin ≥ 10 g\u002FdL\n    * Platelets ≥ 100,000\u002Fmm3\n    * Neutrophils ≥ 1,500\u002Fmm3\n    * Serum creatinine ≤ 1.5 × upper limit of normal (ULN)\n    * Urine protein creatinine ratio (UPCR) \\\u003C 1 or urine dipstick for proteinuria ≤ 2+\n    * Alanine aminotransferase (ALT) \\\u003C 3 × ULN\n    * Aspartate aminotransferase (AST) \\\u003C 3 × ULN\n    * Total bilirubin (TBL) \\\u003C 2 × ULN\n    * Prothrombin time ≤ 1.5 x ULN\n    * International Normalized Ratio (INR) \\\u003C 1.5 These tests must be conducted within 2 weeks prior to the planned first treatment.\n12. The central of FUS exposure region is located close to the cortex, with a minimum distance of at least 30 mm beneath the skull bone.\n13. Females of childbearing potential must have a negative pregnancy test documented within 2 weeks prior to first treatment. Females of childbearing potential and male patients with partners of childbearing potential must agree to adhere to an acceptable method of contraception (as outlined below) from prior to the first study treatment until at least 6 months after the completion of last treatment. Standard acceptable methods of contraception include the use of highly effective methods such as hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, spermicide, vasectomy, intrauterine device, or abstinence from sexual activity.\n14. Patients are able and willing to have peripheral intravenous (IV) line placement of Bevacizumab and are able to have hair shaved (either whole head or in the region where the coupling membrane will touch) prior to FUS treatment.\n15. Patients or their legal representatives are able to provide written informed consent for participation in the trial and patients are willing to comply the procedures (i.e., study-related assessments), instructions, and restrictions outlined in this study in the duration of the study.\n\nExclusion Criteria:\n\n1. Patients who have radiographic evidence of multifocal enhancing tumors.\n2. Patients who have undergone previous treatment with anti-angiogenic therapy, including Bevacizumab, or other VEGF inhibitors or VEGF-receptor signaling inhibitors.\n3. Patients who have previously received Carmustine wafers implantation during re-operation.\n4. Patients who have previously received or are currently undergoing tumor treating fields (TTF) treatment.\n5. Uncontrolled or significant cardiovascular disease, including any of the following:\n\n   * New York Heart Association (NYHA) Grade II or above congestive heart failure (CHF) within 12 months prior to study enrollment\n   * Unstable angina pectoris\n   * Medical history of myocardial infarction within 6 months prior to study enrollment\n   * Cardiac shunt\n6. Stroke (except for transient ischemic attack; TIA) within 6 months prior to study enrollment\n7. Patients with implanted electronic device, for example, implanted cardioverter-defibrillator (ICD), cardiac pacemaker, permanent medication pumps, cochlear implants, responsive neurostimulator (RNS), deep brain stimulation (DBS), or other electronic devices implanted in the brain.\n8. Patients with inadequately controlled hypertension, defined as systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg while on medication, within 2 weeks prior to first treatment.\n9. Patients with evidence of any thrombotic or hemorrhagic events, including but not limited to:\n\n   * Inherited bleeding diathesis or significant coagulopathy with the risk of bleeding (i.e., in the absence of therapeutic anticoagulation).\n   * History of pulmonary haemorrhage\u002Fhaemoptysis ≥ grade 2 according to the CTCAE version 5.0 criteria within 1 month prior to study enrollment.\n   * Arterial or venous thrombosis (e.g., pulmonary embolism) within 6 months prior to study enrollment.\n10. Patients with unstable pulmonary disease or chronic obstructive pulmonary disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study enrollment.\n11. Patients who have psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n12. Know HIV-positive patient, however, that HIV testing is not required for entry into this study.\n13. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study enrollment.\n14. History or evidence of active gastroduodenal ulcer, gastrointestinal perforations\u002Ffistula, or intra-abdominal abscess within 6 months prior to study enrollment.\n15. Receiving anticoagulant (e.g., warfarin or LMW heparin) or antiplatelet (e.g., aspirin) therapy within 1 week prior to beginning treatment.\n16. Known sensitivity\u002Fallergy to Magnetic Resonance Imaging (MRI) contrast agents, Computer Tomography (CT) contrast agents, Lumason® , Avastin® , or any of their components.\n17. Pregnant (positive pregnancy test) or breast-feeding women.\n18. Use of any recreational drugs or history of drug addiction.\n19. Other concurrent severe and\u002For uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection, uncontrolled epilepsy, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol.\n20. Any other condition that, in the Investigator's discretion, might increase the risk to the patients or compromise the evaluation of the clinical trial endpoints.",{"count":147,"type":21},10,[24,149],"PHASE2","This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.",[28,115,62,117,30,46],[119,120,121,123,125,126],{"date":130,"type":91},{"date":155,"type":91},"2024-10-22",{"date":157,"type":21},"2028-03-31",{"name":136,"class":137},1,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":186,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100435367","spanish-series-of-patients-treated-with-the-radionuclide-lutetium177-100435367","NCT04949282","Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU","Inclusion Criteria:\n\n* Written informed consent must be obtained prior to any data collection.\n* Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour\n* Aged ≥18 years.\n\nExclusion Criteria:\n\n* None","100 Years",{"count":170,"type":21},5000,"OBSERVATIONAL","This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.",[174,175,176,177,33,43,44,30,46,178,179,50,180,181,182,183,184,185],"Neuroendocrine Tumors","Intestinal Neoplasms","Pancreatic Neoplasms","Stomach Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Endocrine Gland Neoplasms","Digestive System Diseases","Gastrointestinal Disease","Intestinal Diseases","Pancreatic Disease","Endocrine System Diseases",[187,188,189,190],"GEP-NET","Gastro-Entero-Pancreatic Neuroendocrine Tumour","Luthatera","Somatostatin receptor positive tumour","2022-12-22",{"date":193,"type":91},"2022-12-23",{"date":195,"type":91},"2021-05-10",{"date":197,"type":21},"2035-12-31",{"name":199,"class":98},"Sociedad Española de Medicina Nuclear e Imagen Molecular",20]